Renal cell carcinom
Conditions
Brief summary
Comparison of the area under the concentration-time curve (AUC0-72): calculated by modelling a pharmacokinetic curve from plasma concentrations cabozantinib, obtained by pharmacokinetic samples from 0 to 72 hours after ingestion of cabozantinib. The AUC0-72 of the standard and experimental regimen will be compared. It is defined as comparable if the geometric mean ratio is within the range of 0.8 – 1.25., Comparison of the blood trough concentration (Ctrough): defined as the plasma concentration of cabozantinib before ingestion of a dose of cabozantinib. The Ctrough of the standard and experimental regimen will be compared. It is defined as comparable if the geometric mean ratio is within the range of 0.8 – 1.25.
Detailed description
Health-care use: both medication use and hospitalisations will be registered from the patients’ hospital records, EQ-5D-5L Quality of Life (See Appendix 5): the EQ-5D-5L questionnaire will be taken after at least four weeks on treatment in the first part and after four weeks in the second part., FKSI-19 Quality of Life (See Appendix 6): the FKSI-19 questionnaire will be taken after at least four weeks on treatment in the first part and after four weeks in the second part., Adverse events: defined as any symptom, sign, illness, or untoward experience (including a clinically significant laboratory finding classified as Grade 3 or higher by the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) v5.0) (28) that develops or worsens during the course of the study, whether or not the event is considered related to study drug. Such an event should be recorded as an adverse event only after t, Percentage of patients preferring to take cabozantinib in fed state: Question whether patients would prefer to continue to take cabozantinib in fed state or to recommence taking cabozantinib in fasted state
Interventions
Sponsors
Leids Universitair Medisch Centrum (LUMC)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the area under the concentration-time curve (AUC0-72): calculated by modelling a pharmacokinetic curve from plasma concentrations cabozantinib, obtained by pharmacokinetic samples from 0 to 72 hours after ingestion of cabozantinib. The AUC0-72 of the standard and experimental regimen will be compared. It is defined as comparable if the geometric mean ratio is within the range of 0.8 – 1.25., Comparison of the blood trough concentration (Ctrough): defined as the plasma concentration of cabozantinib before ingestion of a dose of cabozantinib. The Ctrough of the standard and experimental regimen will be compared. It is defined as comparable if the geometric mean ratio is within the range of 0.8 – 1.25. | — |
Secondary
| Measure | Time frame |
|---|---|
| Health-care use: both medication use and hospitalisations will be registered from the patients’ hospital records, EQ-5D-5L Quality of Life (See Appendix 5): the EQ-5D-5L questionnaire will be taken after at least four weeks on treatment in the first part and after four weeks in the second part., FKSI-19 Quality of Life (See Appendix 6): the FKSI-19 questionnaire will be taken after at least four weeks on treatment in the first part and after four weeks in the second part., Adverse events: defined as any symptom, sign, illness, or untoward experience (including a clinically significant laboratory finding classified as Grade 3 or higher by the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) v5.0) (28) that develops or worsens during the course of the study, whether or not the event is considered related to study drug. Such an event should be recorded as an adverse event only after t, Percentage of patients preferring to take cabozantinib in fed state: Q | — |
Countries
Netherlands
Outcome results
None listed